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Purpose. To assess the effects of antioxidant oral supplementation based on docosahexaenoic acid (DHA) in pseudoexfoliative
(PEX) glaucoma. Patients and Methods. A prospective 6-month open-label randomized controlled trial was conducted in patients
with PEX glaucoma and adequate intraocular pressure (IOP) control. Patients in the DHA group received a high-rich DHA (1 g)
nutraceutical formulation. Ophthalmological examination, DHA erythrocyte membrane content (% total fatty acids), plasma total
antioxidant capacity (TAC), plasma malondialdehyde (MDA), and plasma IL-6 levels were assessed. Results. Forty-seven patients
(DHA group 23, controls 24; mean age 70.3 years) were included. In the DHA group, the mean IOP in the right eye decreased from
14.7 [3.3]mmHg at baseline to 12.1 [1.5]mmHg at 6 months (P � 0.01). In the left eye, IOP decreased from 15.1 [3.3]mmHg at
baseline to 12.2 [2.4]mmHg at 6 months (P � 0.007). DHA erythrocyte content increased in the DHA group, with significant
differences versus controls at 3 months and 6 months (8.1% [0.9] vs. 4.4% [0.7]; P< 0.0001). At 6 months and in the DHA group
only, TAC levels as compared with baseline increased significantly (919.7 [117.9] vs. 856.9 [180.3] µM copper-reducing equivalents;
P � 0.01), and both MDA (4.4 [0.8] vs. 5.2 [1.1] nmol/mL; P � 0.02) and IL-6 (2.8 [1.3] vs. 4.7 [2.3] pg/mL; P � 0.006) levels were
lower than in controls. Conclusions. Targeting pathophysiology mechanisms of PEX glaucoma by reducing oxidative stress and
inflammation with a high-rich DHA supplement might be an attractive therapeutic approach. Despite the short duration of
treatment, decrease in IOP supports the clinical significance of DHA supplementation.
1. Introduction
Pseudoexfoliative (PEX) glaucoma has been widely de-
scribed as the result of the accumulation of pseudoexfoliative
material, which obstructs the trabecular meshwork (TM)
leading to an increase in intraocular pressure (IOP) levels.
PEX glaucoma is the most common identifiable secondary
form of open-angle glaucoma, accounting for up to 25% of
glaucoma cases in the world [1, 2]. Compared with primary
open-angle glaucoma, PEX glaucoma is associated with
greater mean IOP, more advanced visual field loss at di-
agnosis, and poorer treatment response [3].
+e etiopathogenetic mechanisms of pseudoexfoliation
syndrome/PEX glaucoma are still not well understood. De-
creased levels of antioxidant capacity might be involved in
glaucomatous TM and neuronal damage as a result of local
inadequate defense against oxidative stress [4, 5]. In the
presence of reactive oxygen species (ROS), nitric oxide
produces toxic metabolites (peroxynitrites) and the associated
oxidative-nitrative stress induces sustained inflammation,
cell proliferation, and/or neurotoxicity [5]. Oxidative DNA
damage is significantly increased in the ocular epithelium
regulating aqueous humor outflow in the TM. Oxidative
damage constitutes an important pathogenetic step–triggering
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TM degeneration, which results in intraocular hypertension
[6]. Also, the transcriptional factor NF-kappaB (NF-kB) can
be activated by increased IOP, increased age, vascular disease,
and oxidative stress [7, 8]. Overstimulation of NF-kB is also
involved in the amplification of the inflammatory cascade [8].
Other studies have shown that interleukin-6 (IL-6) is linked
to the pathogenesis of glaucoma [9]. Dysregulation of
proinflammatory cytokines seems to be implicated in pseu-
doexfoliation syndrome, with high production of IL-6 at early
stages of the disease inducing production of TGF-β1 and fi-
brotic proteins [10]. Moreover, the IL-6 family and their signal
transducer glycoprotein (gp130) have been shown to be in-
volved in inflammation and cell survival in glaucoma [11], as
well as to play a specific role in the progression of retinal
ganglion cell axonopathy from functional deficits to structural
degeneration [12].
In recent years, there has been growing interest of the
health benefits of omega-3 long-chain polyunsaturated fatty
acids (ω-3 PUFAs), particularly docosahexaenoic acid
(DHA), the pleiotropic actions of which may affect mo-
lecular pathways involved in the pathogenesis of ocular
diseases, such as age-related macular edema [13], diabetic
retinopathy and diabetic macular edema [14, 15], and dry
eye syndrome in glaucoma patients [16]. +e rationale of the
use of DHA for improving retinal function is based on the
inhibitory effect of DHA on the activation NF-κB and
synthesis of inflammatory cytokines [17, 18], generation of
eicosanoids and stimulation of inflammation resolving
docosanoids (resolvins and protectins) [19], antiangiogenic
effects of ω-3 PUFAs in human endothelial cells, and an-
tioxidant protective effects on retinal pigment epithelium
and photoreceptors [20, 21]. Recently, dietary consumption
of PUFAs in glaucoma has been proposed as a modifiable
factor for IOP regulation through docosanoids-driven in-
crease of aqueous outflow [22], reversal of ω-3 and ω-6
imbalance in red blood cell membranes [23, 24], and im-
provement of glaucomatous optic neuropathy [25]. How-
ever, the clinical experience with dietary intake of ω-3
PUFAs in glaucoma is very limited [26, 27].
+erefore, a midterm prospective open-label random-
ized controlled trial was conducted to assess the effects of
oral supplementation with a nutraceutical formulation based
on high-rich DHA plus vitamins and minerals in patients
with PEX glaucoma. It was hypothesized that DHA sup-
plementation improves antioxidant protection and ame-
liorates subclinical inflammation in PEX glaucoma.
2. Methods
2.1. Study Design. A prospective, randomized, open-label
controlled study was conducted at the Service of Ophthal-
mology of an acute-care hospital in Ferrol, A Coruña, Spain.
+e duration of the study was 6 months. +e objective of the
study was to determine the effects of daily supplementation
with a nutraceutical formulation rich in DHA plus vitamins
and minerals on clinical and biochemical parameters in
patients with PEX glaucoma. Ethical approval for this study
was provided by the Clinical Research Ethics Committee of
the autonomous community of Galicia, Spain. All participants
provided written informed consent before enrollment. +e
study was conducted in accordance with principles of the
Declaration of Helsinki and guidelines for Good Clinical
Practice. +e study was registered in the European Clinical
Trials Database (EudraCT) (EudraCT trial number 2014-
001104-21 for the Sponsor’s protocol code number:
GLAUPIO).
2.2. Participants. Between July 2016 and February 2017, all
consecutive patients of both sexes aged between 18 and 70
years diagnosed with initial or moderate PEX glaucoma
(stages 1 and 2 of the Hodapp-Parrish-Anderson classifi-
cation) [28] were invited to participate in the study during
an ophthalmologic appointment at the study center. Good
control of IOP with IOP-lowering medications was an in-
clusion criterion. Patients unable to participate in the study
according to the criteria of the ophthalmologist, pregnant
women, and those who refused to sign the written consent
were excluded. Patients using nutritional supplement in-
cluding vitamins, minerals, fatty acids, and trace elements
and those with hypersensitivity to these compounds were
also excluded. Patients were specifically asked if they were
already supplementing their diet with DHA (i.e., fish or flax
seed oil).
2.3. Study Intervention. Each participant contributed 2 study
eyes to the protocol. Study patients were consecutively
assigned with a 1 :1 sequential allocation to the DHA
supplementation (experimental) group or to the control
group using www.random.org (Randomness and Integrity
Services Ltd., Dublin, Ireland). Patients assigned to the
control group met all eligibility conditions, so that the se-
lection criteria (inclusion and exclusion) were identical for
all study patients. Subjects in the control group were masked
regarding the existence of the experimental group. Patients
in the DHA group received a high-rich DHA (1,050mg/day)
nutraceutical formulation (BrudyPio 1.5 g; Brudy Lab, S.L.,
Barcelona, Spain). +is is a concentrated DHA triglyceride
having a high antioxidant activity patented to prevent cel-
lular oxidative damage [29, 30]. Table 1 shows the com-
position of the nutraceutical formulation, which includes
a high dose of DHA (1 g), eicosapentaenoic acid (EPA), and
a mixture of B vitamins, vitamins C, E, lutein, zeaxanthin,
and minerals. All fatty acids were present in the form of
triglycerides (>95%) or ethyl esters (<5%). Patients were
instructed to take 3 capsules of BrudyPio 1.5 g once daily.
Also, patients were told not to change glaucomamedications
during the study.
2.4. Study Procedures. +e duration of the study was 6
months. All patients were evaluated at baseline and at 3 and
6 months thereafter. At each visit, patients underwent
a complete ophthalmologic examination, including slit-lamp
examination, best corrected visual acuity (BCVA) (in dec-
imals), IOP, corneal pachymetry, and retinal nerve fiber
layer thickness (RNFLT) using by spectral-domain optical
coherence tomography (SD-OCT) (Topcon 3D OCT-1000,
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de Topcon Cooperation, Tokyo, Japan). In all participants,
IOP was measured by the same investigator (SRV) using
a Perkins handheld applanation tonometer and during
morning hours between 9:00 and 12:00 AM. Biochemical
analyses included DHA erythrocyte membrane content,
plasma total antioxidant capacity (TAC), plasma malon-
dialdehyde (MDA), and plasma IL-6 levels.
At the baseline visit, eligibility criteria were checked and
patients were fully informed of the purpose of the study and
were requested to sign the informed consent. At the baseline
visit, the nutraceutical formulation was delivered to the patient
for 30-day treatment. +e same assessments as in the baseline
visit were performed at 1, 3, and 6 months (final visit), except
for TAC, MDA, and IL-6 levels which were measured at
baseline and at 6 months. At the 1-month and 3-month visits,
the nutraceutical formulation was provided for the following
60 and 90 days, respectively. Compliance with DHA sup-
plementation was assessed at the study visits by return of
supplementation tablet counts and analytical data especially
erythrocyte membrane DHA content. Ophthalmologists paid
special care to insist on the importance of compliance with the
dietary supplement and the benefit that the patient may re-
ceive from the supplement. At study visits, adverse events were
recorded by questioning the patient. Patients could withdraw
from the study of their own free will or be removed according
to the ophthalmologist’s criteria due to adverse events, con-
comitant diseases, or any other medical reasons.
2.5. Biochemical Analyses. Biochemical measurements in-
cluded the composition of fatty acids on the erythrocyte
membrane (ω-3 DHA) and levels of TAC, MDA, and IL-6 I
plasma samples. +e methods used for assessment of ω-3
DHA in the erythrocyte membrane and plasma TAC and IL-
6 levels have been previously described in detail [31]. +e
content of ω-3 DHA of the erythrocyte membrane was
expressed in percentages as relative amounts of total fatty
acids (FA), plasma TAC as µM copper-reducing equivalent
values, and plasma IL-6 as pg/mL. +e level of MDA was
measured colorimetrically in a Synergy™ H1M, Hybrid
Multi-Mode Microplate Reader (BioTek Instruments, Inc.,
Winooski, VT, USA). +e absorbance was detected at
532 nm. MDA quantitation results are expressed as µmol/L
(µM) concentration using theMDA standard curve obtained
during processing the plasma samples.
2.6. Statistical Analysis. +e sample size of 27 patients per
group (total 54) was calculated based on a variance of 0.048
of TAC plasma levels in PEX glaucoma, with a difference of
0.15, a power of 80%, and a type I error of 0.05. +e sample
size was increased to 30 patients per arm (total 30 patients)
to account for a 10% loss. Categorical variables are expressed
as frequencies and percentages, and continuous variables as
mean and standard deviation (SD). +e chi-squared (χ2) test
or the Fisher’s exact test was used for the analysis of cate-
gorical variables and the Student’s t-test or the Wilcoxon
Table 1: Composition of BrudyPio 1.5 g (Brudy Lab S.L., Barcelona, Spain) per capsule.
Composition Per capsule % recommended dailyamount in one capsule
Per three
capsules
% recommended daily
amount in three capsules
Concentrated oil in ω-3 fatty acids (mg) 500 1,500
TG-DHA 70% 350 — 1,050 —
EPA 8.5% 42.5 — 127.5 —
DPA 6% 30 — 90 —
Vitamins
Vitamin A (retinol, µg) 133.3 17 400 50
Vitamin C (ascorbic acid, mg) 26.7 33 80 100
Vitamin E (d-α-tocopherol, mg) 4 33 12 100
Vitamin B1 (thiamine, mg) 0.36 33 1.1 100
Vitamin B2 (riboflavin, mg) 0.46 33 1.4 100
Vitamin B3 (niacin equivalent, mg) 5.33 33 16 100
Vitamin B6 (pyridoxine, mg) 0.46 33 1.4 100
Vitamin B9 (folic acid, µg) 66.7 33 200 100
Vitamin B12 (cobalamin, µg) 0.83 33 2.5 100
Essential trace elements
Zinc, mg 3.33 33 10 100
Copper, mg 0.33 33 1 100
Selenium, µg 18.3 33 55 100
Manganese, mg 0.66 33 2 100
Other components
Lutein, mg 3.33 — 10 —
Zeaxanthin, mg 0.33 — 1 —
Glutathione, mg 2 — 6 —
Lycopene, mg 2 — 6 —
Coenzyme Q10, mg 2 — 6 —
Anthocyanins, mg 5 — 15 —
Oleuropein, µg 67 — 200 —
TG-DHA: triglyceride-bound DHA; EPA: eicosapentaenoic acid; DPA: docosapentaenoic acid. Note: +e dosage is tested is three capsules per day, which
corresponds to 100% of the recommended daily amounts of the included vitamins and minerals.
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signed-rank test or the Friedman test for the comparison of
quantitative variables according to the conditions of ap-
plication. +e analysis of variance (ANOVA) for repeated
measures (within subject factor: baseline, 3 and 6 months;
between subject factor: experimental or control), with
Bonferroni’s correction was used for the comparison of
study variables collected from the participants throughout
the study. Changes of IOP were analyzed for the right and
left eyes separately, and also as one group (both eyes to-
gether). Statistical significance was set at P< 0.05. Statistical
analyses were performed using the Statistical Package for the
Social Sciences (SPSS®) program (IBM, Armonk, New York,USA) version 21.0.
3. Results
During the study period, a total of 47 patients met the in-
clusion criteria and were included in the study, 23 of which
were randomized to the experimental group and 24 to the
control group. +ere were 25 men and 22 women, with
a mean (SD) of 70.3 (5.0) years. Statistically significant
differences between patients in the study groups regarding
baseline characteristics were not found (Table 2). +e dis-
tribution of comorbid diseases was also similar in the two
study groups.
Patients in the experimental group showed decreases of
IOP from 14.7 (3.3)mmHg at baseline to 13.0 (2.7)mmHg at
3 months (P� 0.072) and 12.1 (1.5)mmHg at 6 months
(P� 0.01) in the right eye. In the left eye, the mean IOP
decreased from 15.1 (3.3)mmHg at baseline to 12.8 (2.6)
mmHg at 3 months (P � 0.042) and 12.2 (2.4)mmHg at 6
months (P � 0.007). In controls, decreased IOP at 6 months
as compared with baseline was not statistically significant
neither in the right or left eyes. Between group differences
for changes of IOP throughout the study were statistically
significant (P � 0.033) for the left eye only (Figures 1 and 2).
+e analysis of both eyes together showed statistically sig-
nificant differences of mean IOP values between 3 and 6
months versus baseline in the experimental group, whereas
in controls decreases of IOP were only significant at 3
months (Table 3). Changes in BCVA and RNFLTduring the
study period were not observed in any of the study groups.
+e content of DHA in the erythrocyte membrane
(% total fatty acids) increased in the experimental group
only, with significant differences as compared with controls
at 3 (7.7 [1.4] vs. 4.4 [0.7] and 6 months (8.1 [0.9] vs. 4.4 [0.7]
(between group differences P< 0.0001). At 6 months and in
the experimental group only, TAC levels as compared with
baseline increased significantly (919.7 [117.9] vs. 856.9
[180.3] µM copper-reducing equivalents; P � 0.01) (between
group differences P � 0.02) (Figure 3).
Also, as shown in Figures 4 and 5, both MDA and IL-6
levels decreased significantly at 6 months versus baseline in
the experimental group only (MDA 4.4 [0.8] vs. 5.0 (0.9) µm,
P� 0.001; and IL-6 2.8 [1.3] versus 4.7 [2.3] pg/mL,
P � 0.006). Between group differences were significant for
both MDA (P � 0.0002) and IL-6 (P � 0.02).
+e nutraceutical formulation was well tolerated, and no
adverse events were registered. In relation to compliance
with the nutraceutical supplement, all patients in the DHA
supplementation group reported having taken the three
capsules each day of the study. Also, none of the patients had
their medications changed during the study.
4. Discussion
In the present series of patients with early or moderate
PEX glaucoma, daily ingestion of a nutraceutical supple-
ment based on high-rich DHA triglyceride plus vitamins
and minerals for 6 months was associated with a trend of
amelioration of IOP and clear improvement of bio-
chemical parameters related to oxidative stress, lipid
peroxidation, and inflammation. +ese midterm results
are encouraging since a simple dietary intervention may
provide an adjunct therapeutic option for patients with
PEX glaucoma.
+e benefits derived from omega-3 supplementation in
patients with glaucoma highlight the potential targets un-
derlying the action of DHA in response to the pathophys-
iological mechanisms of oxidative stress and inflammation
present in open-angle glaucoma. Patients with open-angle
glaucoma exhibit low levels of circulating glutathione,
suggesting a general compromise of the antioxidative de-
fense [32]. Glutathione plays a critical role in many bi-
ological processes in mammalian cells, providing a defense
system for the protection of cells against reactive oxygen
species. During aging, glutathione levels decline, thereby
putting cells at increased risk of succumbing to oxidative
stress [33]. Furthermore, glaucoma patients also show sig-
nificant serum and aqueous humor increase in lipid per-
oxidation levels [34, 35]. +us, oxidative stress may play
a significant role during glaucoma course, initially damaging
the trabecular meshwork, and then contributing to the al-
teration of the homeostasis in ganglionary cells, facilitating
their death [36]. A significant correlation has been shown
among human trabecular meshwork DNA oxidative dam-
age, visual field damage, and IOP [37]. It has also been
proved that the specific activity of superoxide dismutase
demonstrates an age-dependent decline [38]. Moreover,
apoptosis in glaucoma is triggered by endothelial dysregu-
lation and dysfunction, hypoxia, and subclinical in-
flammation. All these conditions might contribute to
accelerate the trabecular meshwork sclerosis favoring IOP
increase and the apoptosis of retinal ganglion cells. Ac-
cordingly, an intervention affecting these mechanisms es-
pecially by decreasing oxidative stress and inflammation
supports the rationale for the study.
However, little is known about the effect of antioxidant
intake and prevention or amelioration of IOP in glaucoma.
In an experimental study carried out in rats, an association
between dietary omega-3 fatty acid intake and decrease in
IOP caused by altered aqueous outflow was found [22].
+e authors of this study suggested that dietary manipu-
lation may provide a modifiable factor for IOP regulation.
Data of clinical studies, however, are sparse. Kant et al. [39]
used a food frequency questionnaire to assess the relation
between the intake of a variety of antioxidants derived from
food and dietary supplements in 474 glaucoma patients
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selected from the Nurses’ Health Study and the Health
Professionals Follow-up Study and followed for more than
10 years and did not observe any strong associations between
antioxidant consumption and the risk of primary open-angle
glaucoma. In a systematic review of 46 articles in which the
effect of nutrients on open-angle glaucoma was studied,
nitric oxide present in dark green leafy vegetables seemed to
have a beneficial effect [27]. Interestingly, Wang et al. [26]
analyzed the association between glaucoma and daily intake
of PUFAs, including ω-3 fatty acids, in 3865 participants in
the National Health and Nutrition Examination Survey
2005–2008 database who were 40 years or older and has
Table 2: Baseline characteristics of the study patients.
Variables Total patients(n � 47)
Study group
P value
Experimental (n � 23) Control (n � 24)
Men/women 25/22 11/12 14/10 0.470
Age, years, mean (SD) 70.3 (5.0) 70.7 (4.5) 69.9 (5.6) 0.563
Comorbid diseases — — — —
Hypertension 19 10 9 —
Dyslipidemia 21 10 11 —
Diabetes mellitus 4 2 2 —
Chronic obstructive pulmonary disease 6 2 4 —
Osteoporosis 5 2 3 —
Ischemic heart disease 2 2 — —
Depression 2 — 2 —
Arthrosis 2 1 1 —
PEX glaucoma — — — 0.765
Right eye 14 (29.8) 7 (30.4) 7 (29.2) —
Left eye 13 (27.6) 5 (21.7) 7 (29.2) —
Both eyes 21 (44.7) 11 (47.8) 10 (41.7) —
BCVA, decimals, mean (SD) — — — —
Right eye 0.90 (0.19) 0.91 (0.22) 0.89 (0.16) 0.735
Left eye 0.86 (0.21) 0.87 (0.19) 0.85 (0.22) 0.776
IOP, mmHg, mean (SD) — — — —
Right eye 14.8 (3.5) 14.7 (3.3) 15.0 (3.7) 0.769
Left eye 14.9 (4.2) 15.1 (3.3) 14.7 (4.9) 0.732
Central corneal thickness, µm, mean (SD) — — — —
Right eye 535.9 (38.6) 543.2 (36.6) 529.0 (40.0) 0.214
Left eye 535.5 (37.5) 540.1 (36.0) 531.1 (39.0) 0.416
RNFLT, µm, mean (SD) — — — —
Right eye 67.8 (22.1) 67.2 (20.5) 68.3 (23.8) 0.880
Left eye 74.5 (19.2) 71.7 (16.4) 76.7 (21.2) 0.416
PEX: pseudoexfoliative; BCVA: best corrected visual acuity; IOP: intraocular pressure; RNFLT: retinal nerve fiber layer thickness.
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Figure 1: Changes of IOP values in the right eye in the experi-
mental and control groups throughout the study.
Control
Experimental
Baseline 6 months
10
12
14
16
Le
ft 
ey
e I
O
P 
(m
m
H
g)
Between group differences p = 0.0332
p = 0.6793
p = 0.0420
p = 0.1306
p = 0.0070
3 months
Figure 2: Changes in IOP values in the left eye in the experimental
and control groups throughout the study.
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available results of eye examinations. Increased levels of
daily dietary intake of EPA (odds ratio [OR] 0.06, 95% CI
0.00–0.73) and DHA (OR 0.06, 95% CI 0.01–0.87) were
associated with significantly lower odds of having glaucoma.
In a previous open study of 1255 patients with glaucoma and
dry eye syndrome treated for 12 weeks with the same nu-
tritional supplement, a significant decrease in IOP values in
both eyes as compared with baseline was observed [16].
+ese findings are consistent with a potential beneficial role
of DHA supplementation in glaucoma patients. +e
nutraceutical product also includes minerals, vitamins, and
other compounds, but the high DHA content is a remarkable
characteristic of the supplement.
Finally, recent studies provided evidence of the associ-
ation between systemic redox status and visual field damage
in glaucoma patients, suggesting that lower systemic anti-
oxidant capacity is associated with more severe visual field
damage in glaucoma disease. Tanito et al. [40] assessed the
correlation between the visual field sensitivity value and
systemic levels of pro-oxidants and antioxidants by ana-
lyzing the blood biochemistry in 202 patients with open-
angle glaucoma (OAG). Univariate and multivariate ana-
lyses suggested a positive correlation between mean value of
visual field sensitivity and systemic levels of antioxidants,
which may indicate that lower systemic antioxidant capacity
is associated with more severe visual field damage in OAG.
In another study, Asano et al. [41] examined the association
between biological antioxidant potential (BAP), a biomarker
of systemic antioxidative capacity, and glaucoma severity in
247 patients (480 eyes) with OAG and 66 healthy controls.
Mixed-effect regression analysis showed that BAP was an
independent contributing factor to glaucomatous damage,
particularly in young males, suggesting that antioxidant
Table 3: Changes of intraocular pressure (IOP) during the study.
Study group
IOP, mmHg, mean (SD)
Right eye P value∗ Left eye P value∗ Both eyes P value∗
Experimental
Baseline 14.7 (3.3) — 15.1 (3.3) 14.9 (3.3) —
3 months 13.0 (2.7) 0.072 12.8 (2.6) 0.04 12.9 (2.6) 0.006
6 months 12.1 (1.5) 0.01 12.2 (2.4) 0.007 12.2 (2.0) 0.0003
Control
Baseline 15.0 (3.7) — 14.7 (4.9) — 14.8 (4.3) —
3 months 12.6 (2.2) 0.016 13.4 (3.2) 0.130 13.0 (2.8) 0.004
6 months 13.4 (3.4) 0.090 14.4 (4.9) 0.679 13.9 (4.2) 0.110∗P values versus baseline for all comparisons.
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Figure 3: Changes of plasma total antioxidant capacity (TAC)
levels in the experimental and control groups throughout the study.
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Figure 4: Serum malondialdehyde (MDA) values decreased sig-
nificantly in the experimental group throughout the study.
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Figure 5: Changes of plasma interleukin- (IL-) 6 values in the
experimental and control groups throughout the study.
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therapy might be more effective in these patients. Bio-
markers of systemic oxidative stress should therefore be
regarded as valuable complementary information sources in
glaucoma care.
Although our findings should be interpreted according
to the small sample size and the limited duration of the
study, further statistically significant reduction of IOP in
patients assigned to the experimental group, who had
otherwise good control of IOP at entry, supports the po-
tential clinical usefulness of DHA supplementation in daily
practice. More studies (longitudinal and randomized clinical
trials) are needed to make the present results clinically
applicable, but they may help ophthalmologists to suggest
their patients an advice on high dietary intake of omega-3
fatty acids.
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